Search

Danaher Corp

Slēgts

SektorsVeselības aprūpe

195.12 -0.64

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

194.63

Max

196.66

Galvenie mērījumi

By Trading Economics

Ienākumi

-159M

870M

Pārdošana

314M

6.3B

P/E

Sektora vidējais

35.027

64.641

EPS

1.94

Dividenžu ienesīgums

0.75

Peļņas marža

13.887

Darbinieki

58,000

EBITDA

-364M

1.1B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+12.72% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

0.75%

2.31%

Nākamie ieņēmumi

2026. g. 20. okt.

Nākamais dividenžu datums

2026. g. 30. okt.

Nākamais Ex dividenžu datums

2026. g. 25. sept.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-4.2B

138B

Iepriekšējā atvēršanas cena

195.76

Iepriekšējā slēgšanas cena

195.12

Ziņu noskaņojums

By Acuity

44%

56%

128 / 340 Rangs Healthcare

Danaher Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 31. jūl. 23:01 UTC

Danaher Corp shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market weakness.

2026. g. 30. jūl. 18:01 UTC

Danaher Corp. shares are lower today, fluctuating within their one-month range amid volatility influenced by the Federal Reserve's interest rate decisions.

2026. g. 29. jūl. 23:01 UTC

Danaher Corp shares are higher in after-market trading, reflecting a slight increase since Wednesday's close. The stock reached a recent high shortly after 5:10 PM ET.

2026. g. 28. jūl. 23:01 UTC

Danaher Corp shares declined in after-hours trading amid broader market losses linked to concerns over artificial intelligence spending and competition from Chinese chipmakers.

2026. g. 27. jūl. 23:16 UTC

Danaher Corp shares are lower in after-market trading, declining slightly since Monday's close. No specific company news has been identified to explain the movement.

2026. g. 24. jūl. 20:06 UTC

News

Danaher Corp shares are lower amid concerns over reduced sales growth in its biotechnology segment, despite raising full-year earnings guidance to $8.45-$8.60.

2026. g. 23. jūl. 10:01 UTC

Danaher Corp shares are lower in pre-market trading, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

2026. g. 22. jūl. 22:01 UTC

Danaher Corp shares are trading lower in after-market hours, continuing a trend of six consecutive sessions finishing lower amid rising crude oil prices and market volatility.

2026. g. 21. jūl. 19:41 UTC

News
Social Media

Danaher Corp shares are lower after the company issued a cautious fiscal 2026 revenue growth forecast despite reporting better-than-expected second-quarter earnings and revenues.

2026. g. 20. jūl. 23:41 UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Salīdzinājums

Cenas izmaiņa

Danaher Corp Prognoze

Cenas mērķis

By TipRanks

12.72% augšup

Prognoze 12 mēnešiem

Vidējais 219.78 USD  12.72%

Augstākais 240 USD

Zemākais 195 USD

Pamatojoties uz 20 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Danaher Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

20 ratings

17

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

128 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat